
1 minute read
&RealEstate Koppel picked for Alzheimer’s advisory board
from Roslyn 2023_02_10
The Alzheimer’s Foundation of America announced the appointment of Dr. Jeremy Koppel, to its Medical, Scientifc & Memory Screening Advisory Board.
Koppel is a longtime physician specializing in geriatric psychiatry and co-director at the Litwin-Zucker Center for the Study of Alzheimer’s Disease at the Feinstein Institutes for Medical Research at Northwell Health, in Manhasset.
Advertisement
AFA’s Medical, Scientifc and Memory Screening Advisory Board is comprised of leading experts in the care, research and treatment of Alzheimer’s disease and related dementias.
AFA relies on advisory board members for expert insight and opinions on scientifc issues surrounding Alzheimer’s disease and related dementias, as well assistance with the development of AFA policies, programs and advocacy eforts related to research and care.
“Dr. Jeremy Koppel is a leading and distinguished researcher and physician who has devoted to his professional career to making a diference for families afected by Alzheimer’s disease,” said Charles J. Fuschillo,Jr., AFA’s president and CEO. “His three decades of experience in research and patient care, together with his passion for helping others, will make him a valuable addition to AFA’s Medical, Scientifc and Memory Screening
Advisory Board. We are proud to welcome him to our team.”
Koppel said, “I am honored by the opportunity to serve on the Medical, Scientifc and Memory Screening Advisory Board of the Alzheimer’s Foundation of America. I look forward to working together with esteemed leaders in the feld who are currently serving on the board with the aim of amplifying new research and improving the lives of patients and families sufering with Alzheimer’s disease.”
Dr. Koppel’s clinical research is focused on providing a new framework for the exploration of novel treatments for psychosis in Alzheimer’s disease.He and his team explore the underlying causes of some of the more disturbing behaviors associated with Alzheimer’s disease, including agitation, hallucinations and aggression, as a means for identifying ways to treat them.